Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaxis Ltd ( (AU:SNT) ) has shared an announcement.
Pharmaxis Ltd has announced positive final Phase 2a data for its drug candidate amsulostat, which is being developed for the treatment of myelofibrosis. This development confirms amsulostat’s competitive profile in the market, potentially enhancing Pharmaxis’s positioning within the pharmaceutical industry and offering promising implications for stakeholders involved in the treatment of myelofibrosis.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 4,424,039
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
Learn more about SNT stock on TipRanks’ Stock Analysis page.